摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

西拉马多 | 63269-31-8

中文名称
西拉马多
中文别名
西拉马朵
英文名称
Ciramadol
英文别名
3-[(R)-dimethylamino-[(1R,2R)-2-hydroxycyclohexyl]methyl]phenol
西拉马多化学式
CAS
63269-31-8
化学式
C15H23NO2
mdl
——
分子量
249.35
InChiKey
UVTLONZTPXCUPU-ZNMIVQPWSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    191-193°
  • 比旋光度:
    D25 -46.92° (c = 1.061 in methanol)
  • 沸点:
    385.7±17.0 °C(Predicted)
  • 密度:
    1.127±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    18
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    43.7
  • 氢给体数:
    2
  • 氢受体数:
    3

文献信息

  • CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY
    申请人:Cerulean Pharma Inc.
    公开号:US20130196906A1
    公开(公告)日:2013-08-01
    Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of a disease or disorder, e.g., autoimmune disease, inflammatory disease, central nervous system disorder, cardiovascular disease, or metabolic disorder. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.
    提供了关于使用CDP-治疗剂偶联物治疗疾病或紊乱的方法,例如自身免疫疾病、炎症性疾病、中枢神经系统紊乱、心血管疾病或代谢紊乱。还提供了CDP-治疗剂偶联物、包含CDP-治疗剂偶联物的颗粒以及包含CDP-治疗剂偶联物的组合物。
  • [EN] PEPTIDE-BASED MULTIPLE-DRUG DELIVERY VEHICLE<br/>[FR] VÉHICULE D'ADMINISTRATION DE MÉDICAMENTS MULTIPLES À BASE DE PEPTIDES
    申请人:ARIEL-UNIVERSITY RES AND DEV COMPANY LTD
    公开号:WO2017068577A1
    公开(公告)日:2017-04-27
    A molecular structure comprising a targeting moiety, a multi-functional peptide platform and a plurality of controllably released bioactive agents attached thereto is provided herein.
    本文提供了一种包括靶向基团、多功能肽平台和附着在其上的多种可控释放的生物活性剂的分子结构。
  • PRODRUGS OF OPIOIDS AND USES THEREOF
    申请人:Franklin Richard
    公开号:US20110190267A1
    公开(公告)日:2011-08-04
    The present invention concerns prodrugs of opioid analgesics and pharmaceutical compositions containing such prodrugs. Methods for providing more consistent pain relief by increasing the bioavailability of the opioid analgesic with the aforementioned prodrugs are provided. The invention also provides for decreasing the adverse GI side effects of opioid analgesics.
    本发明涉及阿片类镇痛药的前药以及含有此类前药的药物组合物。本发明提供了通过前述前药增加阿片类镇痛药生物利用度,从而提供更一致的疼痛缓解方法。该发明还提供了减少阿片类镇痛药对胃肠道的副作用的方法。
  • [EN] THERANOSTIC CONJUGATES<br/>[FR] CONJUGUÉS THÉRANOSTIQUES
    申请人:ARIEL SCIENT INNOVATIONS LTD
    公开号:WO2021009759A1
    公开(公告)日:2021-01-21
    Provided herein is a drug delivery (DD) system for ratiometric luminescence determination of drug release degree in drug delivery monitoring, which includes a drug, a switchable reporter and non-switchable reporter providing two distinguishable signals for detection; or a single switchable reporter providing two distinguishable signals for detection, and a cleavable linker connecting a drug to a switchable reporter, as well as a method for ratiometric luminescence determination of drug release in a target in vivo or in vitro), which is effected by administering the DD system provided herein that is capable of releasing a drug from the DD system, measuring two luminescent signals provided by the switchable reporter and the non-switchable reporter, or the single switchable reporter, determining the ratio between these two luminescence signals, and determining the drug release degree through the ratio between the two luminescence signals.
    本文提供了一种药物递送(DD)系统,用于药物递送监测中药物释放程度的比例荧光测定,该系统包括一种药物、一种可切换的报告物和一种不可切换的报告物,用于提供两种可区分的信号以进行检测;或者一种单一可切换的报告物,用于提供两种可区分的信号以进行检测,以及一种可切割的连接剂,连接药物和可切换的报告物,以及一种比例荧光测定方法,用于在目标(体内或体外)中测定药物释放,通过给予本文提供的能够从DD系统中释放药物的DD系统,测量可切换的报告物和不可切换的报告物提供的两个发光信号,或者单一可切换的报告物,确定这两个发光信号之间的比例,并通过这两个发光信号之间的比例确定药物释放程度。
  • COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE
    申请人:CERULEAN PHARMA INC.
    公开号:US20180193486A1
    公开(公告)日:2018-07-12
    Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.
    提供了关于使用CDP-治疗剂偶联物治疗自身免疫疾病、炎症性疾病或癌症的方法。还提供了CDP-治疗剂偶联物、包含CDP-治疗剂偶联物的颗粒以及包含CDP-治疗剂偶联物的组合物。
查看更多